Preoperative chemotherapy and radiotherapy for esophageal carcinoma

From October 1986 to January 1991, 47 patients with esophageal cancer (29 squamous, 18 adenocarcinoma) were treated with simultaneous radiotherapy (3000 or 3600 cGy) and chemotherapy (infusional 5-fluorouracil, cisplatin) delivered during a 5-week period. This treatment was well tolerated; 44 patien...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The Journal of thoracic and cardiovascular surgery 1992-05, Vol.103 (5), p.887-895
Hauptverfasser: Naunheim, Keith S., Petruska, Paul J., Roy, Tapan S., Andrus, Charles H., Johnson, Frank E., Schlueter, Jean M., Baue, Arthur E.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 895
container_issue 5
container_start_page 887
container_title The Journal of thoracic and cardiovascular surgery
container_volume 103
creator Naunheim, Keith S.
Petruska, Paul J.
Roy, Tapan S.
Andrus, Charles H.
Johnson, Frank E.
Schlueter, Jean M.
Baue, Arthur E.
description From October 1986 to January 1991, 47 patients with esophageal cancer (29 squamous, 18 adenocarcinoma) were treated with simultaneous radiotherapy (3000 or 3600 cGy) and chemotherapy (infusional 5-fluorouracil, cisplatin) delivered during a 5-week period. This treatment was well tolerated; 44 patients (94%) completed a full course of therapy, 40 (85%) had relief from dysphagia, and 21 (45%) noted either weight gain or no net weight loss. One patient (2%) died of complications (tracheoesophageal fistula, perforated ulcer) during chemotherapy and radiotherapy. The remaining 46 patients were referred for operation. Six refused because of excellent relief of their dysphagia, and one was denied operation. Thirty-nine patients went to operation, and 34 (83%) had lesions that were resectable. Eight of the 39 surgically treated patients (21%) had no evidence of residual tumor identified in the resected specimens. One of these complete responders died 7 weeks postoperatively after multiple complications (3% operative mortality rate). Three of the remaining seven have also died since the operation, one of recurrent cancer and two with no known recurrent disease. Actuarial survival in this present series was significantly better than that of our 1980 to 1985 historical control patients (p < 0.005). There was no difference between patients with squamous carcinoma and those with adenocarcinoma with regard to the prevalence of complete response or long-term survival. Survival of the seven patients who did not undergo operation was comparable with that of the 34 patients in whom esophagectomy was performed. This study suggests that combined preoperative chemotherapy plus radiotherapy for esophageal cancer is well tolerated, provides excellent palliation of symptoms, allows for a high rate of resectability, is equally effective for squamous carcinoma and adenocarcinoma, and provides encouraging early results with regard to long-term survival. The data also call into question the role of esophagectomy, particularly in patients who have a complete response to preoperative therapy. (J Thorac Cardiovasc Surg 1992;103:887-95)
doi_str_mv 10.1016/S0022-5223(19)34912-8
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_72900589</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0022522319349128</els_id><sourcerecordid>72900589</sourcerecordid><originalsourceid>FETCH-LOGICAL-c458t-3ac039d5311f61d6707943d15a91853baddb7d3656be2756981166eabeb6540d3</originalsourceid><addsrcrecordid>eNqFkE1P3DAQhq2qiC60PwEpp7YcAp54_XVCaFU-JCSQ2kq9WY49S4ySdWpnt-LfYwiCY0_WeJ53ZvQQcgT0BCiI05-UNk3Nm4Z9B33MlhqaWn0gC6Ba1kLxPx_J4g35RA5yfqCUSgp6n-wDF1pKWJDVXcI4YrJT2GHlOhzi1JVyfKzsxlfJ-vD2sY6pwhzHzt6j7StnkwubONjPZG9t-4xfXt9D8vvix6_VVX1ze3m9Or-p3ZKrqWbWUaY9ZwBrAV5IKvWSeeBWg-Kstd630jPBRYuNLAcqACHQttgKvqSeHZKv89wxxb9bzJMZQnbY93aDcZuNbDSlXOkC8hl0KeaccG3GFAabHg1Q8yzPvMgzz2YMaPMiz6iSO3pdsG0H9O-p2Vbpf5v7Xbjv_oWEJg-27wsN5mFyGSgz3CglC3k2k1h87AImk13AjUNfUm4yPob_3PIEzAqMDw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>72900589</pqid></control><display><type>article</type><title>Preoperative chemotherapy and radiotherapy for esophageal carcinoma</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Naunheim, Keith S. ; Petruska, Paul J. ; Roy, Tapan S. ; Andrus, Charles H. ; Johnson, Frank E. ; Schlueter, Jean M. ; Baue, Arthur E.</creator><creatorcontrib>Naunheim, Keith S. ; Petruska, Paul J. ; Roy, Tapan S. ; Andrus, Charles H. ; Johnson, Frank E. ; Schlueter, Jean M. ; Baue, Arthur E.</creatorcontrib><description>From October 1986 to January 1991, 47 patients with esophageal cancer (29 squamous, 18 adenocarcinoma) were treated with simultaneous radiotherapy (3000 or 3600 cGy) and chemotherapy (infusional 5-fluorouracil, cisplatin) delivered during a 5-week period. This treatment was well tolerated; 44 patients (94%) completed a full course of therapy, 40 (85%) had relief from dysphagia, and 21 (45%) noted either weight gain or no net weight loss. One patient (2%) died of complications (tracheoesophageal fistula, perforated ulcer) during chemotherapy and radiotherapy. The remaining 46 patients were referred for operation. Six refused because of excellent relief of their dysphagia, and one was denied operation. Thirty-nine patients went to operation, and 34 (83%) had lesions that were resectable. Eight of the 39 surgically treated patients (21%) had no evidence of residual tumor identified in the resected specimens. One of these complete responders died 7 weeks postoperatively after multiple complications (3% operative mortality rate). Three of the remaining seven have also died since the operation, one of recurrent cancer and two with no known recurrent disease. Actuarial survival in this present series was significantly better than that of our 1980 to 1985 historical control patients (p &lt; 0.005). There was no difference between patients with squamous carcinoma and those with adenocarcinoma with regard to the prevalence of complete response or long-term survival. Survival of the seven patients who did not undergo operation was comparable with that of the 34 patients in whom esophagectomy was performed. This study suggests that combined preoperative chemotherapy plus radiotherapy for esophageal cancer is well tolerated, provides excellent palliation of symptoms, allows for a high rate of resectability, is equally effective for squamous carcinoma and adenocarcinoma, and provides encouraging early results with regard to long-term survival. The data also call into question the role of esophagectomy, particularly in patients who have a complete response to preoperative therapy. (J Thorac Cardiovasc Surg 1992;103:887-95)</description><identifier>ISSN: 0022-5223</identifier><identifier>EISSN: 1097-685X</identifier><identifier>DOI: 10.1016/S0022-5223(19)34912-8</identifier><identifier>PMID: 1569771</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Actuarial Analysis ; Adenocarcinoma - mortality ; Adenocarcinoma - therapy ; Carcinoma, Squamous Cell - mortality ; Carcinoma, Squamous Cell - therapy ; Chemotherapy, Adjuvant ; Cisplatin - administration &amp; dosage ; Combined Modality Therapy ; Esophageal Neoplasms - mortality ; Esophageal Neoplasms - therapy ; Esophagectomy ; Female ; Fluorouracil - administration &amp; dosage ; Humans ; Male ; Middle Aged ; Preoperative Care ; Radiotherapy, High-Energy</subject><ispartof>The Journal of thoracic and cardiovascular surgery, 1992-05, Vol.103 (5), p.887-895</ispartof><rights>1992 American Association for Thoracic Surgery</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c458t-3ac039d5311f61d6707943d15a91853baddb7d3656be2756981166eabeb6540d3</citedby><cites>FETCH-LOGICAL-c458t-3ac039d5311f61d6707943d15a91853baddb7d3656be2756981166eabeb6540d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/S0022-5223(19)34912-8$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>314,776,780,3536,27903,27904,45974</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/1569771$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Naunheim, Keith S.</creatorcontrib><creatorcontrib>Petruska, Paul J.</creatorcontrib><creatorcontrib>Roy, Tapan S.</creatorcontrib><creatorcontrib>Andrus, Charles H.</creatorcontrib><creatorcontrib>Johnson, Frank E.</creatorcontrib><creatorcontrib>Schlueter, Jean M.</creatorcontrib><creatorcontrib>Baue, Arthur E.</creatorcontrib><title>Preoperative chemotherapy and radiotherapy for esophageal carcinoma</title><title>The Journal of thoracic and cardiovascular surgery</title><addtitle>J Thorac Cardiovasc Surg</addtitle><description>From October 1986 to January 1991, 47 patients with esophageal cancer (29 squamous, 18 adenocarcinoma) were treated with simultaneous radiotherapy (3000 or 3600 cGy) and chemotherapy (infusional 5-fluorouracil, cisplatin) delivered during a 5-week period. This treatment was well tolerated; 44 patients (94%) completed a full course of therapy, 40 (85%) had relief from dysphagia, and 21 (45%) noted either weight gain or no net weight loss. One patient (2%) died of complications (tracheoesophageal fistula, perforated ulcer) during chemotherapy and radiotherapy. The remaining 46 patients were referred for operation. Six refused because of excellent relief of their dysphagia, and one was denied operation. Thirty-nine patients went to operation, and 34 (83%) had lesions that were resectable. Eight of the 39 surgically treated patients (21%) had no evidence of residual tumor identified in the resected specimens. One of these complete responders died 7 weeks postoperatively after multiple complications (3% operative mortality rate). Three of the remaining seven have also died since the operation, one of recurrent cancer and two with no known recurrent disease. Actuarial survival in this present series was significantly better than that of our 1980 to 1985 historical control patients (p &lt; 0.005). There was no difference between patients with squamous carcinoma and those with adenocarcinoma with regard to the prevalence of complete response or long-term survival. Survival of the seven patients who did not undergo operation was comparable with that of the 34 patients in whom esophagectomy was performed. This study suggests that combined preoperative chemotherapy plus radiotherapy for esophageal cancer is well tolerated, provides excellent palliation of symptoms, allows for a high rate of resectability, is equally effective for squamous carcinoma and adenocarcinoma, and provides encouraging early results with regard to long-term survival. The data also call into question the role of esophagectomy, particularly in patients who have a complete response to preoperative therapy. (J Thorac Cardiovasc Surg 1992;103:887-95)</description><subject>Actuarial Analysis</subject><subject>Adenocarcinoma - mortality</subject><subject>Adenocarcinoma - therapy</subject><subject>Carcinoma, Squamous Cell - mortality</subject><subject>Carcinoma, Squamous Cell - therapy</subject><subject>Chemotherapy, Adjuvant</subject><subject>Cisplatin - administration &amp; dosage</subject><subject>Combined Modality Therapy</subject><subject>Esophageal Neoplasms - mortality</subject><subject>Esophageal Neoplasms - therapy</subject><subject>Esophagectomy</subject><subject>Female</subject><subject>Fluorouracil - administration &amp; dosage</subject><subject>Humans</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Preoperative Care</subject><subject>Radiotherapy, High-Energy</subject><issn>0022-5223</issn><issn>1097-685X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1992</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkE1P3DAQhq2qiC60PwEpp7YcAp54_XVCaFU-JCSQ2kq9WY49S4ySdWpnt-LfYwiCY0_WeJ53ZvQQcgT0BCiI05-UNk3Nm4Z9B33MlhqaWn0gC6Ba1kLxPx_J4g35RA5yfqCUSgp6n-wDF1pKWJDVXcI4YrJT2GHlOhzi1JVyfKzsxlfJ-vD2sY6pwhzHzt6j7StnkwubONjPZG9t-4xfXt9D8vvix6_VVX1ze3m9Or-p3ZKrqWbWUaY9ZwBrAV5IKvWSeeBWg-Kstd630jPBRYuNLAcqACHQttgKvqSeHZKv89wxxb9bzJMZQnbY93aDcZuNbDSlXOkC8hl0KeaccG3GFAabHg1Q8yzPvMgzz2YMaPMiz6iSO3pdsG0H9O-p2Vbpf5v7Xbjv_oWEJg-27wsN5mFyGSgz3CglC3k2k1h87AImk13AjUNfUm4yPob_3PIEzAqMDw</recordid><startdate>19920501</startdate><enddate>19920501</enddate><creator>Naunheim, Keith S.</creator><creator>Petruska, Paul J.</creator><creator>Roy, Tapan S.</creator><creator>Andrus, Charles H.</creator><creator>Johnson, Frank E.</creator><creator>Schlueter, Jean M.</creator><creator>Baue, Arthur E.</creator><general>Elsevier Inc</general><general>AATS/WTSA</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19920501</creationdate><title>Preoperative chemotherapy and radiotherapy for esophageal carcinoma</title><author>Naunheim, Keith S. ; Petruska, Paul J. ; Roy, Tapan S. ; Andrus, Charles H. ; Johnson, Frank E. ; Schlueter, Jean M. ; Baue, Arthur E.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c458t-3ac039d5311f61d6707943d15a91853baddb7d3656be2756981166eabeb6540d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1992</creationdate><topic>Actuarial Analysis</topic><topic>Adenocarcinoma - mortality</topic><topic>Adenocarcinoma - therapy</topic><topic>Carcinoma, Squamous Cell - mortality</topic><topic>Carcinoma, Squamous Cell - therapy</topic><topic>Chemotherapy, Adjuvant</topic><topic>Cisplatin - administration &amp; dosage</topic><topic>Combined Modality Therapy</topic><topic>Esophageal Neoplasms - mortality</topic><topic>Esophageal Neoplasms - therapy</topic><topic>Esophagectomy</topic><topic>Female</topic><topic>Fluorouracil - administration &amp; dosage</topic><topic>Humans</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Preoperative Care</topic><topic>Radiotherapy, High-Energy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Naunheim, Keith S.</creatorcontrib><creatorcontrib>Petruska, Paul J.</creatorcontrib><creatorcontrib>Roy, Tapan S.</creatorcontrib><creatorcontrib>Andrus, Charles H.</creatorcontrib><creatorcontrib>Johnson, Frank E.</creatorcontrib><creatorcontrib>Schlueter, Jean M.</creatorcontrib><creatorcontrib>Baue, Arthur E.</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>The Journal of thoracic and cardiovascular surgery</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Naunheim, Keith S.</au><au>Petruska, Paul J.</au><au>Roy, Tapan S.</au><au>Andrus, Charles H.</au><au>Johnson, Frank E.</au><au>Schlueter, Jean M.</au><au>Baue, Arthur E.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Preoperative chemotherapy and radiotherapy for esophageal carcinoma</atitle><jtitle>The Journal of thoracic and cardiovascular surgery</jtitle><addtitle>J Thorac Cardiovasc Surg</addtitle><date>1992-05-01</date><risdate>1992</risdate><volume>103</volume><issue>5</issue><spage>887</spage><epage>895</epage><pages>887-895</pages><issn>0022-5223</issn><eissn>1097-685X</eissn><abstract>From October 1986 to January 1991, 47 patients with esophageal cancer (29 squamous, 18 adenocarcinoma) were treated with simultaneous radiotherapy (3000 or 3600 cGy) and chemotherapy (infusional 5-fluorouracil, cisplatin) delivered during a 5-week period. This treatment was well tolerated; 44 patients (94%) completed a full course of therapy, 40 (85%) had relief from dysphagia, and 21 (45%) noted either weight gain or no net weight loss. One patient (2%) died of complications (tracheoesophageal fistula, perforated ulcer) during chemotherapy and radiotherapy. The remaining 46 patients were referred for operation. Six refused because of excellent relief of their dysphagia, and one was denied operation. Thirty-nine patients went to operation, and 34 (83%) had lesions that were resectable. Eight of the 39 surgically treated patients (21%) had no evidence of residual tumor identified in the resected specimens. One of these complete responders died 7 weeks postoperatively after multiple complications (3% operative mortality rate). Three of the remaining seven have also died since the operation, one of recurrent cancer and two with no known recurrent disease. Actuarial survival in this present series was significantly better than that of our 1980 to 1985 historical control patients (p &lt; 0.005). There was no difference between patients with squamous carcinoma and those with adenocarcinoma with regard to the prevalence of complete response or long-term survival. Survival of the seven patients who did not undergo operation was comparable with that of the 34 patients in whom esophagectomy was performed. This study suggests that combined preoperative chemotherapy plus radiotherapy for esophageal cancer is well tolerated, provides excellent palliation of symptoms, allows for a high rate of resectability, is equally effective for squamous carcinoma and adenocarcinoma, and provides encouraging early results with regard to long-term survival. The data also call into question the role of esophagectomy, particularly in patients who have a complete response to preoperative therapy. (J Thorac Cardiovasc Surg 1992;103:887-95)</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>1569771</pmid><doi>10.1016/S0022-5223(19)34912-8</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0022-5223
ispartof The Journal of thoracic and cardiovascular surgery, 1992-05, Vol.103 (5), p.887-895
issn 0022-5223
1097-685X
language eng
recordid cdi_proquest_miscellaneous_72900589
source MEDLINE; Elsevier ScienceDirect Journals; EZB-FREE-00999 freely available EZB journals
subjects Actuarial Analysis
Adenocarcinoma - mortality
Adenocarcinoma - therapy
Carcinoma, Squamous Cell - mortality
Carcinoma, Squamous Cell - therapy
Chemotherapy, Adjuvant
Cisplatin - administration & dosage
Combined Modality Therapy
Esophageal Neoplasms - mortality
Esophageal Neoplasms - therapy
Esophagectomy
Female
Fluorouracil - administration & dosage
Humans
Male
Middle Aged
Preoperative Care
Radiotherapy, High-Energy
title Preoperative chemotherapy and radiotherapy for esophageal carcinoma
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-21T18%3A39%3A40IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Preoperative%20chemotherapy%20and%20radiotherapy%20for%20esophageal%20carcinoma&rft.jtitle=The%20Journal%20of%20thoracic%20and%20cardiovascular%20surgery&rft.au=Naunheim,%20Keith%20S.&rft.date=1992-05-01&rft.volume=103&rft.issue=5&rft.spage=887&rft.epage=895&rft.pages=887-895&rft.issn=0022-5223&rft.eissn=1097-685X&rft_id=info:doi/10.1016/S0022-5223(19)34912-8&rft_dat=%3Cproquest_cross%3E72900589%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=72900589&rft_id=info:pmid/1569771&rft_els_id=S0022522319349128&rfr_iscdi=true